This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ivabradine oral

Updated 2 Feb 2023 | Other antianginal drugs


Oral formulations of ivabradine.

Drugs List

  • ivabradine 2.5mg tablets
  • ivabradine 5mg tablets
  • ivabradine 7.5mg tablets
  • PROCORALAN 5mg film coated tablets
  • PROCORALAN 7.5mg film coated tablets
  • Therapeutic Indications


    Chronic heart failure with sinus rhythm above 74 bpm
    Chronic stable angina (normal sinus rhythm), heart rate > 69bpm

    Treatment of chronic stable angina pectoris
    Symptomatic treatment of chronic stable angina pectoris in patients with coronary artery disease, with normal sinus rhythm whose heart rate is greater than or equal to 70 beats per minute (bpm), who are either contraindicated for use or intolerant of beta blockers, or in combination with beta blockers in patients inadequately controlled with an optimal beta blocker dose.

    Treatment of chronic heart failure
    Treatment of chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is greater than or equal to 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.



    Treatment of chronic stable angina
    Recommended starting dose of ivabradine should not exceed 5mg twice daily.

    After 3 or 4 weeks the dose may be increased to 7.5mg twice daily depending on the therapeutic response.

    If the patient's heart rate decreases persistently below 50 bpm at rest or bradycardia related symptoms such as dizziness, fatigue or hypotension occur during therapy, reduce the dose by downward titration possibly as low as 2.5mg twice daily if necessary.

    Treatment of chronic heart failure
    Recommended starting dose of ivabradine is 5mg twice daily.

    After 2 weeks the dose may be increased to 7.5mg twice daily if resting heart rate is persistently above 60 bpm.

    If the patient's heart rate decreases persistently below 50 bpm at rest or bradycardia related symptoms such as dizziness, fatigue or hypotension occur during therapy, reduce the dose by downward titration to 2.5mg twice daily if necessary. If the heart rate is between 50 bpm and 60 bpm, the dose of 5mg twice daily should be maintained.


    In patients aged 75 years and over a lower starting dose of 2.5mg twice daily may be considered initially and titrated upwards if necessary.


    Children under 18 years
    Sinus node dysfunction
    Systolic blood pressure < 90mmHg
    Acute phase of cerebrovascular accident
    Bradycardia with pulse rate at rest < 70bpm before treatment of angina
    Bradycardia with pulse rate at rest < 75bpm before tx of heart failure
    Cardiac pacemaker
    Cardiogenic shock
    Long QT syndrome
    Myocardial infarction
    Second degree atrioventricular block
    Severe hepatic impairment
    Sinoatrial exit block
    Third degree atrioventricular block
    Torsade de pointes
    Uncontrolled cardiac failure
    Unstable angina

    Precautions and Warnings

    Family history of long QT syndrome
    Females of childbearing potential
    Patients over 75 years
    Atrial fibrillation
    Bradycardia with a pulse rate of 50 bpm
    Cardiac arrhythmias
    Cardiac conduction defects
    Electrolyte imbalance
    Glucose-galactose malabsorption syndrome
    History of torsade de pointes
    Lactose intolerance
    Moderate hepatic impairment
    New York Heart Association class IV failure
    Prior to electrical cardioversion
    Renal impairment - creatinine clearance below 15ml/minute
    Retinitis pigmentosa

    Control cardiac failure before starting treatment
    Correct electrolyte disorders before treatment
    Advise ability to drive/operate machinery may be affected by side effects
    CHF: Treatment to be initiated and supervised by a specialist
    Reduce initial dose in the elderly
    Contains lactose
    Monitor cardiac function by ECG
    Monitor ECG in patients at risk of QT prolongation
    Monitor for atrial fibrillation
    Monitor for syncope and bradycardia
    Monitor heart rate
    Monitor serum electrolytes
    Review treatment if atrial fibrillation occurs
    Consider discontinuing if visual function deteriorates unexpectedly
    Withhold therapy for 24 hours before elective direct current cardioversion
    Angina: Discontinue if no improvement within 3 months
    Discontinue if pulse rate < 50 beats per minute persists
    Advise patient not to take St John's wort concurrently
    Advise patient to avoid grapefruit products
    Female: Ensure adequate contraception during treatment

    Not recommended in patients with atrial fibrillation or other cardiac arrhythmias which interfere with sinus node function.
    Ivabradine loses its efficacy in the presence of a tachyarrhythmia and is not effective in the treatment or prevention of arrhythmias.

    Chronic heart failure patients with intraventricular conduction defects (bundle branch block left, bundle branch block right) and ventricular dyssynchrony should be monitored closely.

    Not recommended for immediate use following a stroke as there is no data available for these patients.

    Ivabradine may cause transient luminous visual effects (mainly phosphenes) which should be taken into account when considering driving or operating machinery or other situations where sudden variations in light intensity may occur.

    Pregnancy and Lactation


    Ivabradine is contraindicated in pregnancy.

    There is limited data on the use of ivabradine during pregnancy.

    Animal studies have shown embryotoxic and teratogenic effects. The human risk is unknown.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Ivabradine is contraindicated in breastfeeding.

    Animal studies indicated ivabradine is excreted in the breast milk.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal pain
    Atrial extrasystoles
    Atrial fibrillation
    Blood pressure changes
    Blurred vision
    First degree AV block
    Muscle cramps
    Prolongation of QT interval
    Second and third degree AV block
    Serum creatinine increased
    Sick-sinus syndrome
    Ventricular extrasystoles
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2018

    Reference Sources

    Summary of Product Characteristics: Ivabradine 2.5mg tablets. Aspire Pharma Ltd. Revised May 2018.

    Summary of Product Characteristics: Procoralan. Servier Laboratories Ltd. Revised October 2021.

    NICE Evidence Services Available at: Last accessed: 05 September 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.